Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.470
-0.030 (-2.03%)
Oct 6, 2026, 11:00 AM EDT - Market open
Allogene Therapeutics Revenue
Allogene Therapeutics had revenue of $4.64M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $4.64M.
Revenue (ttm)
$4.64M
Revenue Growth
n/a
P/S Ratio
111.69
Revenue / Employee
$30,526
Employees
152
Market Cap
507.72M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 22.00K | -73.00K | -76.84% |
| Dec 31, 2023 | 95.00K | -61.00K | -39.10% |
| Dec 31, 2022 | 156.00K | -113.93M | -99.86% |
| Dec 31, 2021 | 114.09M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 239.66M |
| Puma Biotechnology | 231.24M |
| REGENXBIO | 174.48M |
| Valneva SE | 163.30M |
| Oculis Holding AG | 1.45M |
| YD Bio | 1.24M |
| Neurogene | 925.00K |
| Altimmune | 31.00K |
ALLO News
- 27 days ago - Allogene Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 4 weeks ago - Allogene Therapeutics management to meet with Piper Sandler - TheFly
- 4 weeks ago - Allogene Therapeutics CFO Geoffrey Parker to retire - TheFly
- 4 weeks ago - Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker - GlobeNewsWire
- 5 weeks ago - Allogene Therapeutics Announces Participation in September Investor Conference - GlobeNewsWire
- 7 weeks ago - Allogene Therapeutics files $500M mixed securities shelf - TheFly
- 7 weeks ago - Allogene Therapeutics reports Q2 EPS (13c), consensus (15c) - TheFly
- 7 weeks ago - Allogene Therapeutics Slides: Corporate presentation - Filings